Literature DB >> 17036554

Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.

Chris Kahlenborn1, Francesmary Modugno, Douglas M Potter, Walter B Severs.   

Abstract

OBJECTIVE: To perform a meta-analysis of case-control studies that addressed whether prior oral contraceptive (OC) use is associated with premenopausal breast cancer.
METHODS: We searched the MEDLINE and PubMed databases and bibliography reviews to identify case-control studies of OCs and premenopausal breast cancer published in or after 1980. Search terms used included breast neoplasms, oral contraceptives, contraceptive agents, and case-control studies. Studies reported in all languages were included. Thirty-four studies were identified that met inclusion criteria. Two reviewers extracted data from original research articles or additional data provided by study authors. We used the DerSimonian-Laird method to compute pooled odds ratios (ORs) and confidence intervals (CIs) and the Mantel-Haenszel test to assess association between OC use and cancer.
RESULTS: Use of OCs was associated with an increased risk of premenopausal breast cancer in general (OR, 1.19; 95% CI, 1.09-1.29) and across various patterns of OC use. Among studies that provided data on nulliparous and parous women separately, OC use was associated with breast cancer risk in both parous (OR, 1.29; 95% CI, 1.20-1.40) and nulliparous (OR, 1.24; 95% CI, 0.92-1.67) women. Longer duration of use did not substantially alter risk in nulliparous women (OR, 1.29; 95% CI, 0.85-1.96). Among parous women, the association was stronger when OCs were used before first full-term pregnancy (FFTP) (OR, 1.44; 95% CI, 1.28-1.62) than after FFTP (OR, 1.15; 95% CI, 1.06-1.26). The association between OC use and breast cancer risk was greatest for parous women who used OCs 4 or more years before FFTP (OR, 1.52; 95% CI, 1.26-1.82).
CONCLUSION: Use of OCs is associated with an increased risk of premenopausal breast cancer, especially with use before FFTP in parous women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036554     DOI: 10.4065/81.10.1290

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  49 in total

1.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

2.  RCGP's oral contraception study: Study shows greater cancer risk.

Authors:  Joel Brind
Journal:  BMJ       Date:  2008-01-12

3.  Hormonal contraception--what kind, when, and for whom?

Authors:  Inka Wiegratz; Christian J Thaler
Journal:  Dtsch Arztebl Int       Date:  2011-07-18       Impact factor: 5.594

4.  Oral contraceptive use among women in the military and the general U.S. population.

Authors:  Lindsey Enewold; Louise A Brinton; Katherine A McGlynn; Shelia H Zahm; John F Potter; Kangmin Zhu
Journal:  J Womens Health (Larchmt)       Date:  2010-05       Impact factor: 2.681

5.  Half a century of the oral contraceptive pill: historical review and view to the future.

Authors:  Pamela Verma Liao; Janet Dollin
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

6.  Age-standardized cancer-incidence trends in Canada, 1971-2015.

Authors:  Darren R Brenner; Yibing Ruan; Eileen Shaw; Dylan O'Sullivan; Abbey E Poirier; Emily Heer; Paul J Villeneuve; Stephen D Walter; Christine M Friedenreich; Leah Smith; Prithwish De
Journal:  CMAJ       Date:  2019-11-18       Impact factor: 8.262

Review 7.  Application of electrospun fibers for female reproductive health.

Authors:  Anna K Blakney; Yonghou Jiang; Kim A Woodrow
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

8.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006.

Authors:  Tsogzolmaa Dorjgochoo; Xiao-Ou Shu; Hong-Lan Li; Han-Zhu Qian; Gong Yang; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

9.  Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.

Authors:  Murray Joseph Casey; Todd A Salzman
Journal:  Linacre Q       Date:  2018-07-20

10.  Quality of systematic reviews of observational nontherapeutic studies.

Authors:  Tatyana Shamliyan; Robert L Kane; Stacy Jansen
Journal:  Prev Chronic Dis       Date:  2010-10-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.